

# Hironobu Minami

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1739704/hironobu-minami-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

97  
papers

1,943  
citations

24  
h-index

42  
g-index

104  
ext. papers

2,421  
ext. citations

4.2  
avg, IF

4.35  
L-index

#	Paper	IF	Citations
97	Apixaban in Japanese patients with cancer-associated venous thromboembolism: a multi-center phase II trial.. <i>International Journal of Hematology</i> , <b>2022</b> , 1	2.3	0
96	Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge.. <i>Molecular and Clinical Oncology</i> , <b>2022</b> , 16, 104	1.6	0
95	Phase I study of the antiprogrammed cell death-1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies. <i>Cancer Science</i> , <b>2021</b> , 112, 725-733	6.9	3
94	Global Longitudinal Strain Is Superior to Ejection Fraction for Long-Term Follow-up after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , <b>2021</b> , 138, 1824-1824	2.2	
93	Increase in Antibody Titers Following Sars-Cov-2 Vaccination Remains Limited for More Than 3 Years after Final Dose of Anti-CD20 Antibody. <i>Blood</i> , <b>2021</b> , 138, 534-534	2.2	1
92	Regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission: A case report. <i>Molecular and Clinical Oncology</i> , <b>2021</b> , 14, 30	1.6	0
91	Five-year survival with nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma. <i>Journal of Dermatology</i> , <b>2021</b> , 48, 592-599	1.6	0
90	Incidence of venous thromboembolism in patients with solid cancers in Japan: retrospective study of 2735 patients. <i>International Journal of Hematology</i> , <b>2021</b> , 114, 319-324	2.3	0
89	Guidelines for clinical evaluation of anti-cancer drugs. <i>Cancer Science</i> , <b>2021</b> , 112, 2563-2577	6.9	5
88	Immunosuppressive effects and mechanisms of three myeloid-derived suppressor cells subsets including monocytic-myeloid-derived suppressor cells, granulocytic-myeloid-derived suppressor cells, and immature-myeloid-derived suppressor cells. <i>Journal of Cancer Research and Therapeutics</i> , <b>2021</b> , 17, 1093-1100	1.2	2
87	Secondary -rearranged sarcoma responsive to chemotherapy regimens for Ewing sarcoma: A case report. <i>Molecular and Clinical Oncology</i> , <b>2021</b> , 14, 68	1.6	2
86	A phase I, dose-escalation study of oral PIM447 in Japanese patients with relapsed and/or refractory multiple myeloma. <i>International Journal of Hematology</i> , <b>2021</b> , 113, 797-806	2.3	2
85	Did the Randomized Phase III KEYNOTE-181 Study of Pembrolizumab for Esophageal Cancer Yield Negative or Positive Results?. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2317-2318	2.2	1
84	Massive surge of mRNA expression of clonal B-cell receptor in patients with COVID-19. <i>Heliyon</i> , <b>2021</b> , 7, e07748	3.6	1
83	Adipsin-Dependent Secretion of Hepatocyte Growth Factor Regulates the Adipocyte-Cancer Stem Cell Interaction. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
82	Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 5771-5780	12.9	1
81	Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study. <i>International Journal of Clinical Oncology</i> , <b>2021</b> , 26, 2205-2215	4.2	0

80	Microsatellite instability-high colorectal cancer patient-derived xenograft models for cancer immunity research.. <i>Journal of Cancer Research and Therapeutics</i> , <b>2021</b> , 17, 1358-1369	1.2	0
79	Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer.. <i>Journal of Infection and Chemotherapy</i> , <b>2021</b> ,	2.2	1
78	Band 3 ectopic expression in colorectal cancer induces an increase in erythrocyte membrane-bound IgG and may cause immune-related anemia. <i>International Journal of Hematology</i> , <b>2020</b> , 111, 657-666	2.3	1
77	COT-17 Cancer genomic medicine at Kobe University Hospital. <i>Neuro-Oncology Advances</i> , <b>2020</b> , 2, ii22-ii23.	2.3	1
76	Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia. <i>Cancer Science</i> , <b>2020</b> , 111, 1314-1323	6.9	8
75	Upregulation of S100A10 in metastasized breast cancer stem cells. <i>Cancer Science</i> , <b>2020</b> , 111, 4359-4370.	6.9	5
74	Disseminated cryptococcosis resembling miliary tuberculosis in a patient with acute myeloid leukemia. <i>Journal of Infection and Chemotherapy</i> , <b>2020</b> , 26, 1216-1219	2.2	0
73	Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naive advanced melanoma. <i>Journal of Dermatology</i> , <b>2020</b> , 47, 1257-1266	1.6	6
72	Lymphoplasmacytic lymphoma in a patient with Birt-Hogg-Dubé syndrome. <i>International Journal of Hematology</i> , <b>2020</b> , 112, 864-870	2.3	0
71	Phase I Study of LFA102 in Patients With Advanced Breast Cancer or Castration-resistant Prostate Cancer. <i>Anticancer Research</i> , <b>2020</b> , 40, 5229-5235	2.3	3
70	Detection of a novel CBFβ-MYH11 fusion transcript in acute myeloid leukemia M1 with inv(16)(p13q22). <i>Cancer Genetics</i> , <b>2020</b> , 241, 72-76	2.3	1
69	Long-term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma. <i>Cancer Science</i> , <b>2019</b> , 110, 1995-2003	6.9	19
68	Phase I study of BGT226, a pan-PI3K and mTOR inhibitor, in Japanese patients with advanced solid cancers. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 84, 337-343	3.5	4
67	Pharmacokinetic study of the oral fluorouracil antitumor agent S-1 in patients with impaired renal function. <i>Cancer Science</i> , <b>2019</b> , 110, 1987-1994	6.9	5
66	Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib. <i>Leukemia Research</i> , <b>2019</b> , 79, 38-44	2.7	20
65	miR-221 Targets QKI to Enhance the Tumorigenic Capacity of Human Colorectal Cancer Stem Cells. <i>Cancer Research</i> , <b>2019</b> , 79, 5151-5158	10.1	38
64	Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial. <i>Cancer Science</i> , <b>2019</b> , 110, 2894-2904.	6.9	28
63	Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 2315-2326	59.2	114

62	Adipose-derived stem cells enhance human breast cancer growth and cancer stem cell-like properties through adipisin. <i>Oncogene</i> , <b>2019</b> , 38, 767-779	9.2	54
61	A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 83, 289-299	3.5	6
60	Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive acute myeloid leukemia. <i>Journal of Oncology Pharmacy Practice</i> , <b>2019</b> , 25, 2010-2015	1.7	0
59	Coexpression of ETV6/MDS1/EVI1 and ETV6/EVI1 fusion transcripts in acute myeloid leukemia with t(3;12)(q26.2;p13) and thrombocytosis. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 1294-1298	1.9	1
58	Successful Bridging Chemotherapy with Gemcitabine, Carboplatin, and Dexamethasone before Unrelated Stem Cell Transplantation for Hepatosplenic T-cell Lymphoma. <i>Internal Medicine</i> , <b>2019</b> , 58, 707-712	1.1	3
57	A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. <i>Future Oncology</i> , <b>2019</b> , 15, 717-726	3.6	68
56	Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2018</b> , 81, 839-846	3.5	0
55	Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. <i>International Journal of Hematology</i> , <b>2018</b> , 107, 83-91	2.3	7
54	Invasive Scopulariopsis albiflavescens infection in patient with acute myeloid leukemia. <i>International Journal of Hematology</i> , <b>2018</b> , 108, 658-664	2.3	6
53	Efficacy and safety of nivolumab (Nivo) in patients (pts) with advanced or recurrent uterine cervical or corpus cancers.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 5594-5594	2.2	14
52	Phase II study of a combination therapy of nivolumab, bevacizumab and paclitaxel in patients with HER2-negative metastatic breast cancer as a first-line treatment (WJOG9917B, NEWBEAT trial).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS1110-TPS1110	2.2	4
51	A Case of Classical Hodgkin Lymphoma with Total Lymph Node Infarction. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , <b>2018</b> , 58, 24-26	1.9	3
50	Adapalene gel 0.1% vs. placebo as prophylaxis for anti-EGFR-induced acne-like rash: A randomized left-right comparative evaluation (APPEARANCE).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 10093-10093	2.2	
49	Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study. <i>European Journal of Cancer</i> , <b>2018</b> , 105, 114-126	7.5	31
48	Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma. <i>Case Reports in Oncology</i> , <b>2018</b> , 11, 735-741	1	9
47	Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria. <i>Auris Nasus Larynx</i> , <b>2018</b> , 45, 1249-1252	2.2	6
46	Quality of life and cost-utility of surgical treatment for patients with spinal metastases: prospective cohort study. <i>International Orthopaedics</i> , <b>2017</b> , 41, 1265-1271	3.8	12
45	Phase I study of glasdegib (PF-04449913), an oral smoothed inhibitor, in Japanese patients with select hematologic malignancies. <i>Cancer Science</i> , <b>2017</b> , 108, 1628-1633	6.9	37

44	Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma. <i>Cancer Science</i> , <b>2017</b> , 108, 1022-1031	6.9	66
43	Prospective Cohort Study of Performance Status and Activities of Daily Living After Surgery for Spinal Metastasis. <i>Clinical Spine Surgery</i> , <b>2017</b> , 30, E1026-E1032	1.8	12
42	NANOG Expression as a Responsive Biomarker during Treatment with Hedgehog Signal Inhibitor in Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	16
41	Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study. <i>Cancer Science</i> , <b>2017</b> , 108, 1223-1230	6.9	47
40	Constitutional t(8;22)(q24;q11.2) that mimics the variant Burkitt-type translocation in Philadelphia chromosome-positive chronic myeloid leukemia. <i>International Journal of Hematology</i> , <b>2017</b> , 105, 226-229 <sup>2,3</sup>		
39	Roles of microRNAs and RNA-Binding Proteins in the Regulation of Colorectal Cancer Stem Cells. <i>Cancers</i> , <b>2017</b> , 9,	6.6	23
38	Lenvatinib for Anaplastic Thyroid Cancer. <i>Frontiers in Oncology</i> , <b>2017</b> , 7, 25	5.3	109
37	A prospective study of the antiemetic effect of palonosetron in malignant lymphoma patients treated with the CHOP regimen. <i>International Journal of Hematology</i> , <b>2016</b> , 104, 682-691	2.3	6
36	Validity of new methods to evaluate renal function in cancer patients treated with cisplatin. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2016</b> , 77, 281-8	3.5	15
35	Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy. <i>Blood</i> , <b>2016</b> , 128, 625-625	2.2	12
34	Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer: Final analysis results.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 6088-6088	2.2	17
33	Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors. <i>Cancer Science</i> , <b>2016</b> , 107, 1477-1483	6.9	15
32	Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. <i>Auris Nasus Larynx</i> , <b>2016</b> , 43, 677-84	2.2	27
31	The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2016</b> , 77, 1165-70	3.5	10
30	Chemotherapy-induced Nausea and Vomiting in Patients with Hepatobiliary and Pancreatic Cancer Treated with Chemotherapy: A Prospective Observational Study by the CINV Study Group of Japan. <i>Anticancer Research</i> , <b>2016</b> , 36, 1929-35	2.3	4
29	Effect of Xenotransplantation Site on MicroRNA Expression of Human Colon Cancer Stem Cells. <i>Anticancer Research</i> , <b>2016</b> , 36, 3679-86	2.3	5
28	Mediastinal Germ Cell Tumor Exhibiting a Discrepancy between Tumor Markers and Imaging: A Case Study. <i>Case Reports in Oncology</i> , <b>2015</b> , 8, 323-31	1	
27	MicroRNA Regulation of Human Breast Cancer Stem Cells. <i>Journal of Clinical Medicine</i> , <b>2015</b> , 5,	5.1	60

26	Absence of primary cilia in cell cycle-arrested human breast cancer cells. <i>Genes To Cells</i> , <b>2014</b> , 19, 141-52.	2.3	29
25	Metabolomics evaluation of serum markers for cachexia and their intra-day variation in patients with advanced pancreatic cancer. <i>PLoS ONE</i> , <b>2014</b> , 9, e113259	3.7	29
24	Alterations in HbA1c resulting from the donation of autologous blood for elective surgery in patients with diabetes mellitus. <i>Blood Transfusion</i> , <b>2014</b> , 12 Suppl 1, s209-13	3.6	5
23	Transcriptional expression of Bcl-2 as predictive of response to neoadjuvant chemotherapy with trastuzumab in HER2-positive ER-positive breast cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 602-602	2.2	
22	Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2579-2579	2.2	1
21	TYRO3 as a potential therapeutic target in breast cancer. <i>Anticancer Research</i> , <b>2014</b> , 34, 3337-45	2.3	21
20	A phase I study of tasisulam sodium using an albumin-tailored dose in Japanese patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 71, 991-8	3.5	5
19	Prediction of glomerular filtration rate in cancer patients by an equation for Japanese estimated glomerular filtration rate. <i>Japanese Journal of Clinical Oncology</i> , <b>2013</b> , 43, 271-7	2.8	14
18	A randomized multicenter phase II trial on efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 9623-9623	2.2	
17	Pathologic complete response to cisplatin with dose-dense paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: Preliminary results of a multicenter phase II study with additional mutation analysis of adeno/adenosquamous carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 5528-5528	2.2	
16	Eribulin mesylate in patients with refractory cancers: a Phase I study. <i>Investigational New Drugs</i> , <b>2012</b> , 30, 1926-33	4.3	48
15	Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. <i>Investigational New Drugs</i> , <b>2012</b> , 30, 1055-64	4.3	48
14	Global survey on barriers to clinical cancer research.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e16505-e16505	2.5	
13	Sorafenib-associated hand-foot syndrome in Japanese patients. <i>Journal of Dermatology</i> , <b>2011</b> , 38, 261-6.	1.6	18
12	Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients. <i>Cancer Science</i> , <b>2010</b> , 101, 963-8	6.9	52
11	Phase I dose escalation and pharmacokinetic study of oral enzastaurin (LY317615) in advanced solid tumors. <i>Cancer Science</i> , <b>2010</b> , 101, 2193-9	6.9	12
10	An overview of the recent progress in irinotecan pharmacogenetics. <i>Pharmacogenomics</i> , <b>2010</b> , 11, 391-406	6.6	34
9	Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. <i>Cancer Science</i> , <b>2009</b> , 100, 144-9	6.9	28

8	Clinical trial simulations for dosage optimization of docetaxel in patients with liver dysfunction, based on a log-binominal regression for febrile neutropenia. <i>Yakugaku Zasshi</i> , <b>2009</b> , 129, 749-57	0	9
7	Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. <i>Cancer Science</i> , <b>2008</b> , 99, 1492-8	6.9	101
6	Haplotypes and a novel defective allele of CES2 found in a Japanese population. <i>Drug Metabolism and Disposition</i> , <b>2007</b> , 35, 1865-72	4	22
5	Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. <i>Pharmacogenetics and Genomics</i> , <b>2007</b> , 17, 497-504	1.9	227
4	Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2). <i>Drug Metabolism and Disposition</i> , <b>2005</b> , 33, 1482-7	4	40
3	Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients?. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 2901-8	2.2	81
2	Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. <i>Pharmacogenetics and Genomics</i> , <b>2003</b> , 13, 741-57		126
1	Re: prediction of carboplatin clearance from standard morphological and biological patient characteristics. <i>Journal of the National Cancer Institute</i> , <b>1997</b> , 89, 968-70	9.7	10